Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.

Cancer letters - 28 Sept 2012

Zhang Xiang-Hua, Shin Jung-Young, Kim Jeong-Oh, Oh Ji-Eun, Yoon Seong-Ae, Jung Chan-Kwon, Kang Jin-Hyoung

Abstract excerpt

Studies on non-small cell lung cancer (NSCLC) patients with KRAS or BRAF mutations are urgently needed to improve clinical outcomes. We evaluated the cytotoxicities of paclitaxel and sorafenib alone and in combination in NSCLC cell lines with KRAS or BRAF mutations and investigated the mechanism of the interaction between the drugs. We found synergistic antitumor efficacy with paclitaxel followed by sorafenib in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Niacinamide

Share to Paclitaxel

Share to Phenylurea Compounds

Share to Retinoblastoma Protein

Share to Sorafenib

Source

Identifiers

PMID: 22433711
DOI: 10.1016/j.canlet.2012.03.015

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.PMID 22433711Read ↗

Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.Semantic proximity Read ↗

Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.Semantic proximity Read ↗

Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.Semantic proximity Read ↗

Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.Semantic proximity Read ↗

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid TumorsSemantic proximity Read ↗

Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.Semantic proximity Read ↗

Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.Semantic proximity Read ↗

SH003 enhances the anti-cancer effects of Dabrafenib on lung cancer harboring BRAF G469A mutation by inhibiting the MAPK signaling pathwaySemantic proximity Read ↗

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.Semantic proximity Read ↗

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.Semantic proximity Read ↗

ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.Semantic proximity Read ↗

The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.